ISCoPE - Transverse myelitis
Research type
Research Study
Full title
Injured spinal cord pressure evaluation study - Transverse myelitis
IRAS ID
173947
Contact name
Marios C. Papadopoulos
Contact email
Sponsor organisation
St George's University of London
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Transverse myelitis (TM) is a rare inflammatory condition of the spinal cord. It is characterised by rapid onset of motor, sensory or autonomic dysfunction causing neurological deficit. It has a diverse range of causes; most commonly it is associated with multiple sclerosis and neuromyelitis optica also known as Devic's disease or Devic's syndrome, is a heterogeneous condition consisting of the simultaneous inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis). It affects approximately 1900 adults and children in the UK annually, with 350 cases per year of unknown cause.
Outcome in TM is variable; e.g. neuromyelitis optica mortality was 30% . There is a relationship between the severity of neurological symptoms at presentation and the eventual outcome. When a patient is ASIA (American spinal injuries association) A or tetraplegic at presentation, they are less likely to recover than when ASIA B/C or paraplegic. Approximately 30% of patients will be ASIA A-C after a TM episode.
There are several pathological mechanisms which could increase the risk of decreased blood supply and further neurological deficit in TM. In our ISCoPE study we showed that in traumatic spinal cord injury when swelling causes mechanical compression of the cord against the dura there is increased intra spinal pressure (ISP).
We propose to monitor the ISP and spinal cord metabolites in 10 TM patients with MRI evidence of a swollen enlarged spinal cord. There has never been a study looking at ISP in TM patients before. The optimum blood pressure in patients with TM is not known.
We aim to observe a previously unrecognised pathological mechanism of injury in TM. In the future this could lead on to novel treatments to improve drug delivery and neurological outcome in a condition otherwise associated with a poor outcome.REC name
London - Westminster Research Ethics Committee
REC reference
16/LO/1432
Date of REC Opinion
29 Nov 2016
REC opinion
Further Information Favourable Opinion